Catalyst Brief

← Calendar

Readoutin 14d

Vanda Pharmaceuticals — VQW-765

Phase 3 primary completion: Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder.

Date
Dec 2026
Type
Readout
Indication
Social Anxiety Disorder (SAD)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.